Clinical evidence and reporting standards in reirradiation: Insights from 28 studies at ESTRO 2025, endorsed by the ESTRO reirradiation focus group.

ABSTRACT:

Background

Reirradiation (reRT) has become an increasingly relevant treatment option across multiple tumor sites, supported by technological advances that improve precision and safety. At the ESTRO 2025 Annual Meeting, 28 clinical studies on reRT were presented. This work provides a structured synthesis of their clinical outcomes and assesses adherence to the ESTRO-EORTC reporting recommendations.

Materials and methods

All abstracts presented at ESTRO 2025 (n = 2,962) were screened to identify reRT studies (n = 51). Only studies reporting at least one clinical outcome were retained (n = 28). ReRT was classified as type 1 (with geometric overlap of irradiated volumes) or type 2 (without overlap but with potential OAR dose concerns). Each study was evaluated using the 10 manda

SUBMITTER: Beddok A 

PROVIDER: S-EPMC12752745 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature